Surgery Partners shares fall after Q1 call highlights volume headwinds, robotics investment

Surgery Partners (SGRY) traded at $13.79 after its first-quarter earnings call, down 2.9% from $14.20 before the report, as investors weighed above-expectation revenue growth against pressure on case volumes. Management said results were supported by stable performance across surgical facilities, early recovery in previously pressured hospital markets and a shift toward higher-acuity procedures. CEO Eric Evans cited improved operating consistency, investments in surgical robotics and expansion of musculoskeletal services as drivers. The company also faced weather-related disruptions in lower-acuity markets. Key issues for coming quarters include physician onboarding, new center ramp-ups, cost controls, payer mix pressure, provider taxes, potential asset divestitures and possible M&A activity later in 2026.